Price T Rowe Associates Inc. MD Grows Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Price T Rowe Associates Inc. MD grew its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 7.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,108,617 shares of the company's stock after buying an additional 219,498 shares during the period. Price T Rowe Associates Inc. MD owned about 1.39% of Sana Biotechnology worth $5,068,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of SANA. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $29,000. Tower Research Capital LLC TRC grew its holdings in Sana Biotechnology by 229.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after purchasing an additional 10,548 shares during the last quarter. Cerity Partners LLC acquired a new position in shares of Sana Biotechnology during the 4th quarter worth about $25,000. Blue Trust Inc. grew its stake in shares of Sana Biotechnology by 51.0% in the fourth quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock worth $32,000 after acquiring an additional 6,694 shares during the last quarter. Finally, Ieq Capital LLC acquired a new position in Sana Biotechnology during the 4th quarter valued at $32,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Stock Performance

NASDAQ:SANA remained flat at $1.81 on Friday. 4,343,618 shares of the company's stock traded hands, compared to its average volume of 3,321,148. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $9.49. The firm's 50-day simple moving average is $1.95 and its two-hundred day simple moving average is $2.50. The firm has a market cap of $408.11 million, a PE ratio of -1.29 and a beta of 1.75.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. Research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SANA has been the topic of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a research report on Thursday, April 24th. Jefferies Financial Group began coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a "buy" rating and a $7.00 target price for the company. Finally, Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research report on Tuesday, March 18th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Sana Biotechnology presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.